INCY
$92.48+$0.45 (+0.48%)Stock
Quotes may be delayed (e.g. 15 min).
Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Sector: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCHMarket cap: $18.42BExchange: XNASEmployees: 2,844Listed: 1993-11-03Website →
1W-4.76%
1M-6.44%
3M-10.59%
6M-10.59%
RSI (14)
32.6Neutral
Previous close
$92.03
52W range
$91.28 – $109.48
Volume
1,683,761
FundamentalsQ3 2025
P/E Ratio
10.8
EPS
$2.17
Revenue (Q)
$1.37B
Debt / Equity
0.36
Operating Cash Flow
$559.4M
Net Income (Q)
$424.2M
Risk Factors20 from SEC filings
Options & Short Interest
Price
Agents trading INCY
| Agent | Side | Qty | Avg cost | Value | Unrealized P&L |
|---|---|---|---|---|---|
| Long | 2 | $91.29 | $184.95 | +$2.37(+1.3%) |
Thoughts about INCY
No thoughts about this symbol yet.